Antisense treatments for biothreat agents

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 2, 2006, Pages 93-103

  Warfield, Kelly L ^a   Panchal, Rekha G ^b   Aman, M Javad ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Antisense; Biothreat; Oligonucleotide; Phosphorodiamidate morpholino; Phosphorothioate; Small interfering RNA

Indexed keywords

2' O METHOXYETHYL OLIGONUCLEOTIDE DERIVATIVE; 2' O METHYL OLIGONUCLEOTIDE DERIVATIVE; 2' O METHYLOLIGORIBONUCLEOTIDE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; ANTISENSE PHOSPHOROTHIOATE OLIGONUCLEOTIDE DERIVATIVE; ARGININE DERIVATIVE; CGP 69846A; CLUSTERIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; FOMIVIRSEN; GENE EXPRESSION MODULATOR 231; ISIS 2503; MESSENGER RNA; METHYLPHOSPHONATE OLIGODEOXYNUCLEOTIDE DERIVATIVE; NAKED DNA; OBLIMERSEN; OGX 011; OLIGODEOXYRIBONUCLEOSIDE METHYLPHOSPHONATE; OLIGONUCLEOTIDE; PHOSPHORODIAMIDATE MORPHOLINO OLIGONUCLEOTIDE DERIVATIVE; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE DERIVATIVE; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN BCL 2; RAF PROTEIN; RIBONUCLEASE H; SINGLE STRANDED RNA; SIRNA 027; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VIRUS RNA;

ANGIOGENESIS; ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; BINDING AFFINITY; BIOLOGICAL WARFARE; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOMEGALOVIRUS INFECTION; DENGUE; DENGUE VIRUS; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MIXTURE; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; DRUG TRANSPORT; EBOLA VIRUS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; FILOVIRUS; FLAVIVIRUS; GENE EXPRESSION; GENE SILENCING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERGLYCEMIA; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MUSCLE ATROPHY; NONHUMAN; NONVIRAL GENE THERAPY; ONCOGENE H RAS; PROTEIN MODIFICATION; PROTEIN SECONDARY STRUCTURE; RETINITIS; REVIEW; RNA BINDING; SIDE EFFECT; THROMBOCYTOPENIA; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS INHIBITION;

ANIMALS; BIOTERRORISM; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING;

BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS; DENGUE VIRUS; EBOLA VIRUS; FLAVIVIRUS; HEPATITIS C VIRUS; MARBURGVIRUS; NEGIBACTERIA; POSIBACTERIA; PRIMATES;

EID: 33645711222     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS et al. Hemorrhagic fever viruses as biological weapons: Medical and public health management J Am Med Assoc (2002) 287(18):2391-2405.
2. Wiliams P, Wallace D: Unit 731, Japan's Secret Biological Warfare in World War II. Free Press, New York, NY, USA (1989):38-40.
3. Alibek K, Handelman S (Eds): Biohazard. Random House, New York, NY, USA (1999).
4. Miller J, Engelberg S, Broad W (Eds): Germs: Biological Weapons and America's Secret War. Simon & Schuster, New York, NY, USA (2001).
5. Center for Nonproliferation Studies: Chemical and biological weapons: Possession and programs past and present. Company Web Site (2000). http://cns.miis.edu/research/cbw/possess.htm
6. Richmond JY, McKinney RW (Eds): Biosafety in Microbiological and Biomedical Laboratories, 4th Edition. US Department of Heath and Human Services, Centers for Disease Control and Prevention, NIH, MD, USA (1999):1-258.
7. Burnett J, Henchal EA, Schmaljohn A, Bavari S: The evolving field of biodefence: Therapeutic developments and diagnostics. Nat Rev Drug Discov (2005) 4(4):281-297.
8. Stephenson ML, Zamecnik PC: Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA (1978) 75(1):285-288.
9. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA (1978) 76(1):280-284.
10. Stein CA, Matsukura M, Subasinghe C, Broder S, Cohen JS: Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV. AIDS Res Hum Retroviruses (1989) 5(6):639-646.
11. Crooke S: Basic principles of antisense technology. In: Antisense Drug Technology- Principles: Strategies, and Applications. Crooke S (Ed), Marcel Dekker Inc, New York, NY, USA (2001):1-28.
12. Dirksen ML, Crouch RJ: Selective inhibition of RNase H by dextran. J Biol Chem (1981) 256(2):11569-11573.
13. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM: Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem (1993) 268(19):14514-14522.
14. McKay RA, Cummins LL, Graham MJ, Lesnik EA, Owens SR, Winniman M, Dean NM: Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-α by the incorporation of 2′-O-propyl modifications. Nucleic Acids Res (1996) 24(3):411-417.
15. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM, Bennett CF: 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule I (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem (1997) 272(18):11994-12000.
16. Monia BP, Johnston JF, Sasmor H, Cummins LL: Nuclease resistance and antisense activity of modified oligonucleotides targeted to Haras. J Biol Chem (1996) 271(24):14533-14540.
17. Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H, Fabbro D: Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA (1996) 93(26):15481-15484.
18. Lesnik EA, Guinosso CJ, Kawasaki AM, Sasmor H, Zounes M, Cummins LL, Ecker DJ, Cook PD, Freier SM: Oligodeoxynucleotides containing 2′-O-modified adenosine: Synthesis and effects on stability of DNA:RNA duplexes. Biochemistry (1993) 32(30):7832-838.
19. Freier SM, Altmann KH: The ups and downs of nucleic acid duplex stability: Structure-stability studies on chemically-modified DNA: RNA duplexes. Nucleic Acids Res (1997) 26(22):4429-4443.
20. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, Dean NM: Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol (2000) 18(8):862-867.
21. Agrawal S, Mayrand SH, Zamecnik PC, Pederson T: Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides. Proc Natl Acad Sci USA (1990) 87(4):1401-1405.
22. Yamaguchi K, Papp B, Zhang D, Ali AN, Agrawal S, Byrn RA: The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1997) 13(7):545-554.
23. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T, Broberger C, Porreca F, Lai J, Ren K, Ossipov M et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA (2000) 97(10):5633-5638.
24. Geary RS, Henry SP, Grillone LR: Fomivirsen: Clinical pharmacology and potential drug interactions. Clin Pharmacokinet (2002) 41(4):255-260.
25. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD: Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev (1996) 6(4):267-272.
26. Giles RV, Spiller DG, Clark RE, Tidd DM: Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev (1999) 9(2):213-220.
27. Iversen P: Phophorodiamidate morpholino oligomers. In: Antisense Drug Technology: Principles, Strategies, and Applications. Crooke ST (Ed), Marcel Dekker Inc, New York, NY, USA (2001):375-389.
28. Neuman BW, Stein DA, Kroeker AD, Paulino AD, Moulton HM, Iversen PL, Buchmeier MJ: Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth. J Virol (2004) 78(11):5891-5899.
29. Nasevicius A, Ekker SC: Effective targeted gene 'knockdown' in zebrafish. Nat Genet (2000) 26(2):216-220.
30. Moulton HM, Hase MC, Smith KM, Iversen PL: HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev (2003) 13(1):31-43.
31. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL: Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem (2004) 15(2):290-299.
32. Summerton J, Weller D: Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev (1997) 7(3):187-195.
33. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun (2002) 296(4):1000-1004.
34. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 211-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
35. Meister G, Landthaler M, Dorsett Y, Tuschl T: Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA (2004) 10(3):544-550.
36. Tomari Y, Zamore PD: Perspective: Machines for RNAi. Genes Dev (2005) 19(5):517-529.
37. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA: RNA interference in adult mice. Nature (2002) 418(6893):38-39.
38. Sato Y, Ajiki T, Inoue S, Fujishiro J, Yoshino H, Igarashi Y, Hakamata Y, Kaneko T, Murakamid T, Kobayashi E: Gene silencing in rat-liver and limb graft by rapid injection of small interference RNA. Transplantation (2005) 79(2):240-243.
39. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther (2005) 12(5):461-466.
40. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432(7014):173-178.
41. 14C-labeled phosphorothioate oligonucleotide ISIS 2106 after intravenous administration to rats. J Pharmacol Exp Ther (1993) 267(3):1181-1190.
42. Agrawal S, Temsamani J, Tang JY: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA (1991) 88(17):7595-7599.
43. Yu RZ, Geary RS, Monteith DK, Matson J, Truong L, Fitchett J, Levin AA: Tissue disposition of 2′-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci (2004) 93(1):48-59.
44. Noll BO, McCluskie MJ, Sniatala T, Lohner A, Yuill S, Krieg AM, Schetter C, Davis HL, Uhlmann E: Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. Biochem Pharmacol (2005) 69(6):981-991.
45. Krieg AM, Stein CA: Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein? Antisense Res Dev (1995) 5(4):241.
46. Nicklin PL, Bayley D, Giddings J, Craig SJ, Cummins LL, Hastewell JG, Phillips JA: Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes. Pharm Res (1998) 15(4):583-591.
47. Soler M, McHutchison JG, Kwoh TJ, Dorr FA, Pawlotsky JM: Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir Ther (2004) 9(6):953-968.
48. Olie RA, Hall J, Natt F, Stahel RA, Zangemeister-Wittke U: Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide. Biochim Biophys Acta (2002) 1576(1-2):101-109.
49. Amantana A, Iversen PL: Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol (2005) 6(5):550-555.
50. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR: Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin Cancer Res (2003) 9(7):2510-2519.
51. Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL: In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AV-4126, in solid tumors. Clin Cancer Res (2005) 11(10):3930-3938.
52. Braasch DA, Paroo Z, Constantinescu A, Ren G, Oz OK, Mason RP, Corey DR: Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett (2004) 14(5):1139-1143.
53. Whelan J: First clinical data on RNAi: Drug Disc Today (2005) 10(15):1014-1015.
54. Villinger F, Rollin PE, Brar SS, Chikkala NF, Writer J, Sundstrom JB, Zaki SR, Swanepoel R, Ansari AA, Peters CJ: Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J Infect Dis (1999) 179(Suppl 1):S188-S191.
55. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E: Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol (2001) 124(3):453-460.
56. Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, Aman MJ, Yokoyama WM, Young HA, Bavari S: Role of natural killer cells in innate protection against lethal Ebola virus infection. J Exp Med (2004) 200(2):169-179.
57. Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S: Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol (2005) 175(2):1184-1191.
58. Feldmann H, Kiley MP: Classification, structure, and replication of filoviruses. Curr Top Microbiol Immunol (1999) 235:1-21.
59. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP: Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet (2003) 362(9400):1953-1958.
60. Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, Bavari S: Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2(1):e1.
61. Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, Kroeker AD, Iversen PL, Bavari S, Mühlberger E: VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 50(3):984-993.
62. Fowler T, Bamberg S, Moller P, Klenk HD, Meyer TF, Becker S, Rudel T: Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol (2005) 86(Pt 4):1181-1188.
63. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PS, McClintock K, Phelps JR et al: Postexposure protection of guinea pigs against a lethal Ebola Virus challenge by RNA interference. J Infect Dis (2006): in press.
64. Pinheiro FP, Corber SJ: Global situation of dengue and dengue hemorrhagic fever and its emergence in the Americas. World Health Stat Q (1997) 50(3-4):161-168.
65. Kinney RM, Huang CY-H, Rose BC, Kroeker AD, Dreher TW, Iversen PL, Stein DA: Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. J Virol (2005) 79(8):5116-5128.
66. Holden KL, Stein DA, Pierson TC, Ahmed AA, Clyde K, Iversen PL, Harris E: Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3′ stem-loop structure. Virology (2006) 344(2):439-452.
67. Hahn CS, Hahn YS, Rice CM, Lee E, Dalgamo L, Strauss EG, Strauss JH: Conserved elements in the 3′ untranslated region of flavivinis RNAs and potential cyclization sequences. J Mol Biol (1987) 198(1):33-41.
68. Khromykh AA, Meka H, Guyatt KJ, Westaway EG: Essential role of cyclization sequences in flavivirus RNA replication. J Virol (2001) 75(14):6719-6728.
69. Deas TS, Binduga-Gajewska I, Tilgner M, Ren P, Stein DA, Moulton HM, Iversen PL, Kauffman EB, Kramer LD, Shi PY: Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol (2005) 79(8):4599-4609.
70. Geller BL: Antibacterial antisense. Curr Opin Mol Ther (2005) 7(2):109-113.
71. Geller BL, Deere J, Tilley L, Iversen PL: Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis. J Antimicrob Chemother (2005) 55(6):983-988.
72. Good L, Nielsen PE: Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat Biotechnol (1998) 16(4):355-358.
73. Good L, Nielsen PE: Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA. Proc Natl Acad Sci USA (1998) 96(5):2073-2076.
74. Good L, Sandberg R, Larsson O, Nielsen PE, Wahlestedt C: Antisense PNA effects in Escherichia coli are limited by the outer-membrane LPS layer. Microbiology (2000) 146(Pt 10):2665-2670.
75. Geller BL, Deere JD, Stein DA, Kroeker AD, Moulton HM, Iversen PL: Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers. Antimicrob Agents Chemother (2003) 47(10):3233-3239.
76. Harth G, Zamecnik PC, Tang J-Y, Tabatadze O, Horwitz MA: Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication. Proc Natl Acad Sci USA (2000) 97(1):418-423.
77. Harth G, Horwitz MA, Tabatadze D, Zamecnik PC: Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technology. Proc Natl Acad Sci USA (2002) 99(24):15614-15619.
78. Deere J, Iversen P, Geller BL: Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli. Antimicrob Agents Chemother (2005) 49(1):249-255.
79. Gait MJ: Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell Mol Life Sci (2003) 60(5):844-853.
80. Stetsenko DA, Arzumanov AA, Korshun VA, Gait MJ: [Peptide-oligonucleotide conjugates as a new generation of antisense elements]. Mol Biol Mosk (2000) 34(6):998-1006.
81. Good L, Awasthi SK, Dryselius R, Larsson O, Nielsen PE: Bactericidal antisense effects of peptide-PNA conjugates. Nat Biotechnol (2001) 19(4):360-364.
82. Nekhotiaeva N, Awasthi SK, Nielsen PE, Good L: Inhibition of Staphylococcus aureus gene expression and growth using antisense peptide nucleic acids. Mol Ther (2004) 10(4):652-659.
83. Boiziau C, Blonski C, Thuong NT, Shire D, Toulme JJ: Inhibition of reverse transcription by unmodified and modified antisense oligodeoxynucleotides. Nucleic Acids Symp Ser (1991) (24):121-125.
84. Boiziau C, Thuong NT, Toulme JJ: Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides. Proc Natl Acad Sci USA (1992) 89(2):768-772.
85. Smith AW, Matson DO, Stein DA, Skilling DE, Kroeker AD, Berke T, Iversen PL: Antisense treatment of caliciviridae: An emerging disease agent of animals and humans. Curr Opin Mol Ther (2002) 4(2):177-184.
86. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng BJ, Woodle MC, Zhong N et al: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med (2005) 11(9):944-951.
87. Neuman BW, Stein DA, Kroeker AD, Churchill MJ, Kim AM, Kuhn P, Dawson P, Moulton HM, Bestwick RK, Iversen PL, Buchmeier MJ: Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J Virol (2005) 79(15):9665-9676.
88. Sankar S, Cheah KC, Porter AG: Antisense oligonucleotide inhibition of encephalomyocarditis virus RNA translation. Eur J Biochem (1989) 184(1):39-45.
89. Pagano JS, Jimenez G, Sung NS, Raab-Traub N, Lin JC: Epstein-Barr viral latency and cell immortalization as targets for antisense oligomers. Ann NY Acad Sci (1992) 660:107-116.
90. Masciarelli S, Mattioli B, Galletti R, Samoggia P, Chichiarelli S, Mearini G, Mattia E: Antisense to Epstein Barr Virus-encoded LMP1 does not affect the transcription of viral and cellular proliferation-related genes, but induces phenotypic effects on EBV-transformed B lymphocytes. Oncogene (2002) 21(26):4166-4170.
91. van den Born E, Stein DA, Iversen PL, Snijder EJ: Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture. J Gen Virol (2005) 86(Pt 11):3081-3090.
92. Ropert C, Lavignon M, Dubernet C, Couvreur P, Malvy C: Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochem Biophys Res Commun (1992) 183(2):879-885.
93. Matsukura M, Koike K Zon G: Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Toxicol Left (1995) 82-83:435-438.
94. Yao ZQ, Zhou YX, Feng XM, Chen ZX: Specific inhibition of hepatitis B virus gene expression by an antisense oligonucleotide in vitro. Acta Virol (1995) 39(4):227-230.
95. Yao Z, Zhou Y, Feng X, Chen C, Guo J: In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice. J Viral Hepatitis (1996) 3(1):19-22.
96. Tan TM, Zhou L, Houssais S, Seet BL, Jaenicke S, Peter F, Lim SG: Intracellular inhibition of hepatitis B virus S gene expression by chimeric DNA-RNA phosphorothioate minimized ribozyme. Antisense Nucleic Acid Drug Dev (2002) 12(4):257-264.
97. Tallet-Lopez B, Aldaz-Carroll L, Chabas S, Dausse E, Staedel C, Toulme JJ: Antisense oligonucleotides targeted to the domain IIId of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent in vitro translation. Nucleic Acids Res (2003) 31(2):734-742.
98. Nulf CJ, Corey D: Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES)-dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs). Nucleic Acids Res (2004) 32(13):3792-3798.
99. Sarin PS, Agrawal S, Civeira MP, Goodchild J, Ikeuchi T, Zamecnik PC: Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proc Natl Acad Sci USA (1988) 85(20):7448-7451.
100. Goodchild J, Agrawal S, Civeira MP, Sarin PS, Sun D, Zamecnik PC: Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc Natl Acad Sci USA (1988) 85(15):5507-5511.
101. Stevenson M, Iversen PL: Inhibition of human immunodeficiency virus type 1-mediated cytopathic effects by poly(L-lysine)-conjugated synthetic antisense oligodeoxyribonucleotides. J Gen Virol (1989) 70(Pt 10):2673-2682.
102. Agrawal S, Ikeuchi T, Sun D, Sarin PS, Konopka A, Maizel J, Zamecnik PC: Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci USA (1989) 86(20):7790-7794.
103. Matsukura M, Zon G, Shinozuka K, Robert-Guroff M, Shimada T, Stein CA, Mitsuya H, Wong-Staal F, Cohen JS, Broder S: Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci USA (1989) 86(11):4244-4248.
104. Mori K, Boiziau C, Cazenave C, Matsukura M, Subasinghe C, Cohen JS, Broder S, Toulme JJ, Stein CA: Phosphoroselenoate oligodeoxynucleotides: Synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity. Nucleic Acids Res (1989) 17(20):8207-8219.
105. Letsinger RL, Zhang GR, Sun DK, Ikeuchi T, Sarin PS: Cholesteryl-conjugated o ligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci USA (1989) 86(17):6553-6556.
106. Buck HM, Koole LH, van Genderen MH, Smit L, Geelen JL, Jurriaans S, Goudsmit J: Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity. Science (1990) 248(4952):208-212.
107. Farooqui F, Sarin PS, Sun D, Letsinger RL: Effect of structural variations in cholesteryl-conjugated oligonucleotides on inhibitory activity toward HIV-1. Bioconjug Chem (1991) 2(6):422-426.
108. Laurence J, Sikder SK Kulkosky J, Miller P, Ts'o PO: Induction of chronic human immunodeficiency virus infection Is blocked in vitro by a methylphosphonate oligodeoxynucleoside targeted to a U3 enhancer element. J Virol (1991) 65(1):213-219.
109. Zamecnik PC, Agrawal S: Oligodeoxynucleotide hybridization inhibition of HIV and influenza virus. Nucleic Acids Symp Ser (1991) (24):127-131.
110. Kim SG, Hatta T, Tsukahara S, Nakashima H, Yamamoto N, Shoji Y, Takai K, Takaku H: Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus. Bioorg Med Chem (1995) 3(1):49-54.
111. Kuwasaki T, Hosono K, Takai K, Ushijima K, Nakashima H, Saito T, Yamamoto N, Takaku H: Hairpin antisense oligonucleotides containing 2′-methoxynucleosides with base-pairing in the stem region at the 3′-end: Penetration, localization, and anti-HIV activity. Biochem Biophys Res Commun (1996) 228(2):623-631.
112. Boiziau C, Tarrago-Litvak L, Sinha ND, Moreau S, Litvak S, Toulme J-J: Antisense oligonucleotides inhibit in vitro cDNA synthesis by HIV-1 reverse transcriptase. Antisense Nucleic Acid Drug Dev (1996) 6(2):103-109.
113. Hamma T, Miller PS: Interactions of hairpin oligo-2′-O-methylribonucleotides containing methylphosphonate linkages with HIV TAR RNA. Antisense Nucleic Acid Drug Dev (2003) 13(1):19-30.
114. Darfeuille F, Hansen JB, Orum H, Di Primo C, Toulme JJ: LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1. Nucleic Acids Res (2004) 32(10):3101-3107.
115. Gao WY, Hanes RN, Vazquez-Padua MA, Stein CA, Cohen JS, Cheng YC: Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides. Antimicrob Agents Chemother (1990) 34(5):808-812.
116. Kmetz ME, Ceruzzi M, Schwartz J: Vmw65 phosphorothioate oligonucleotides inhibit HSV KOS replication and Vmw66 protein synthesis. Antiviral Res (1991) 16(2):173-184.
117. Leonetti JP, Machy P, Degols G, Lebleu B, Leserman L: Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc Natl Acad Sci USA (1990) 87(7):2448-2451.
118. Kean JM, Kipp SA, Miller PS, Kulka M, Aurelian L: Inhibition of herpes simplex virus replication by antisense oligo-2′-O-methylribonucleoside methylphosphonates. Biochemistry (1995) 34(45):14617-14620.
119. Aurelian L, Smith CC: Herpes simplex virus type 2 growth and latency reactivation by cocultivation are inhibited with antisense oligonucleotides complementary to the translation initiation site of the large subunit of ribonucleotide reductase (RR1). Antisense Nucleic Acid Drug Dev (2000) 10(2):77-85.
120. Alonso M, Stein DA, Thomann E, Moulton HM, Leong JC, Iversen P, Mourich DV: Inhibition of infectious haematopoietic necrosis virus in cell cultures with peptide-conjugated morpholino oligomers. J Fish Dis (2005) 28(7):399-410.
121. Archambault D, Stein CA, Cohen JS: Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses. Arch Virol (1994) 139(1-2):97-109.
122. Shan YF, Gao HY, Ji H, Qiu MS, Wang DB: Antiviral effects on mouse leukemia virus replication by oligodeoxynucleotides in vitro and in vivo. Chin Med J (Engl) (1994) 107(2):146-150.
123. Leaman DW, Longano FJ, Okicki JR, Soike KF, Torrence PF, Silverman RH, Cramer H: Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-6A antisense. Virology (2002) 292(1):70-77.
124. Crum C, Johnson JD, Nelson A, Roth D: Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro. Nucleic Acids Res (1988) 16(10):4569-4581.
125. Degols G, Leonetti JP, Gagnor C, Lemaitre M, Lebleu B: Antiviral activity and possible mechanisms of action of oligonucleotides-poly(L-lysine) conjugates targeted to vesicular stomatitis virus mRNA and genomic RNA. Nucleic Acids Res (1989) 17(22):9341-9350.
126. Shea RG, Marsters JC, Bischofberger N: Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates. Nucleic Acids Res (1990) 18(13):3777-3783.
127. Levis JT, Miller PS: Interactions of psoralen-derivatized oligodeoxyribonucleoside methylphosphonates with vesicular stomatitis virus messenger RNA. Antisense Res Dev (1994) 4(4):223-230.
128. Stein DA, Skilling DE, Iversen PL, Smith AW. Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev (2001) 11(5):317-325.